Global Digestive Enzymes Market

The gastric cancer drugs market consists of sales of drugs for gastric cancer. Gastric cancer, also known as stomach cancer, is the formation of abnormal cells on the lining of stomach resulting in stomach pain and indigestion. The market covered in the gastric cancer drugs market report is segmented by type into doxorubicin hydrochloride, sunitinib, docetaxel, mitomycin, fluorouracil, imatinib, trastuzumab; by end user into hospitals, clinics, others; by route of administration into oral, parenteral. The global gastric cancer drugs market is expected to decline from $2.9 billion in 2020 to $2.88 billion in 2021 at a compound annual growth rate (CAGR) of -0.7%. The slow decline is mainly due to the outbreak of COVID-19 that has led to deferment of immunocompromised treatments. The gastric cancer drugs market is expected to reach $3.1 billion in 2025 at a CAGR of 1.9%. Increasing number of obesity cases and smoking population increased number of people suffering from gastric cancer. Consuming tobacco and following diet unhealthy diet increases the risk of stomach cancer. According to the estimates of American Institute for Cancer Research for 2020, about 27,600 cases of stomach cancer will be diagnosed (16,980 in men and 10,620 in women). Increase in number of cases in gastric cancer will drive the market for gastric cancer drugs. Stringent regulations and policies for approval of the drugs restrain the market for gastric cancer drugs. Different regions have their own set of rules, guidelines and regulations set by their respective drugs regulation board. For example, the USFDA regulations for American pharmaceuticals states various conditions with regards to safety and effectiveness of the drug as well as certain labeling requirements. Similarly, the European medicines agency (EMA) gives licenses to the approved drugs before they can be marketed or commercialized in the European continent. Teysuno, a drug for advanced gastric cancer can be only obtained through a valid prescription and the protocol is that every company must assess the effects of using Teysuno and must list out the precautions to be taken by patients and healthcare providers to minimize any possible side effects. These regulations hinder the growth of the gastric cancer drugs market. Many companies are using combination therapies to cure gastric cancer. Combination therapies help in treating patients with two or more drugs for a single disease and help in better treating the patients. For instance, in 2019, the USFDA has approved Taiho Oncology Inc’s combined product LONSURF trifluridine/tipiracil for pre-treated metastatic gastric cancer. This approval is significant for patients living with advanced gastric or GEJ (gastroesophageal junction) adenocarcinoma who have limited effective treatment options after failure of standard treatment options. Advances in the drugs for treatment of gastric cancer will have a positive influence on the gastric cancer drugs’ market. The gastric cancer drugs market is regulated by government agencies such as European Medicines Agency (EMA), USFDA (the US food and drug ministration), and others. For instance, FDA's Current Good Manufacturing Practice (CGMP) regulation lays down minimum requirements for the methods and facilities used in manufacturing, processing, and packing of a drug product and ensures the quality of drugs produced by manufacturers. Moreover, FDA's guidance provides recommendations to applicants for cancer clinical trials and shows support in new drug applications (NDAs), biologics license applications (BLAs), or supplemental applications. On April 2019, AstraZeneca, a multinational pharmaceutical and biopharmaceutical company acquired Daiichi Sankyo for $1.35 billion. This acquisition will help AstraZeneca to jointly develop drug Trastuzumab Deruxtecan with Daiichi Sankyo. This drug would help to treat people suffering from breast and gastric cancer. Daiichi Sankyo headquarted at Japan is a global pharmaceutical company which offers innovative products and a robust pipeline for cancer treatment. Major players in the gastric cancer drugs market are Eli Lilly and company, Novartis, Merck KGaA, Otsuka Pharmaceutical, and F. Hoffmann-La Roche. The regions covered in the gastric cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the gastric cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global gastric cancer drugs market is segmented - 1) By Type: Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab 2) By End User: Hospitals, Clinics, Others 3) By Route of Administration: Oral, Parenteral

The endoscopy devices and equipment market consists of sales of endoscopy devices and equipment which are used to diagnose the diseases or examine the interiors of organs. The global endoscopy devices and equipment market is expected to grow from $4.92 billion in 2020 to $5.49 billion in 2021 at a compound annual growth rate (CAGR) of 11.6%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $7.8 billion in 2025 at a CAGR of 9.2%. Rise in incidence and prevalence rates of gastrointestinal (GI) diseases is driving the endoscopy devices and equipment market. The increasing incidence of gastrointestinal diseases such as colorectal cancer, gastroesophageal reflux disease, ulcerative colitis (UC), inflammatory bowel disease (IBD), and crohn’s disease (CD) are supporting the endoscopy devices and equipment market. The endoscopy devices are used in performing non-invasive or minimally invasive surgical procedures to treat life-threatening diseases. The Asian countries have the highest prevalence rates of gastrointestinal diseases such as cancer. In 2018, according to World Cancer Research Fund, stomach cancer is the fourth commonly occurring cancer in men and the seventh commonly occurring cancer in women. Globally 1,033,701 new cases diagnosed as stomach cancer. South Korea had the highest rate of stomach cancer in 2018, followed by Mongolia. In Korea, with every 39.6 persons per 100,000 suffering from cancer, Mangolia with 33.1 per 100,000 and Japan with 27.5 per 100,000 ranked as 1, 2, and 3 respectively. Due to the rising prevalence of GI diseases, developing countries are experiencing high demand for minimally invasive surgical procedures, increasing the demand for endoscopy devices. Regulatory changes are likely to increase costs related to new product development and service offerings to clients. These changes are related to customer data protection such as the European Union's General Data Protection Regulation (GDPR), changes to equipment approval procedures and other regulatory changes. For instance, according to a report by Ernst and Young (EY) in 2018, Fortune 500 companies are spending $7.8 billion to comply with GDPR regulations. The GDPR regulation is an EU law on data protection and privacy of individuals residing the European Union and the European Economic Area (EEA). It also regulates the export of personal data outside the EU and EEA areas. Additionally, the FDA is requesting more clinical data to support claims, therefore increasing the time to process 510(k) by over 55% over the last decade. The potential loss of revenue due to delay in product release and additional costs incurred due to stringent approval processes puts strain on investments relating to new product development, thereby affecting the growth of the market. Companies in the endoscopy devices and equipment market are increasingly developing endoscopy robotic systems as they are more flexible, effective than the conventional endoscopy devices. These robotic endoscopy devices help in eliminating difficulties in therapeutic endoscopy, expanding endoscopy’s vision and reach, reducing labor intensity, improve communication, reach, vision, control, and the ability to perform an endoscopy. These devices are used in gastrointestinal surgeries, urology/gynecology surgeries, ENT surgeries, cardiovascular surgeries, neuro/spinal surgeries, laparoscopy surgeries and arthroscopy surgical applications. In 2018, Medineering announced the use of its robotic solution-Medineering Robotic Endoscopy. Furthermore, companies such as Johns Hopkins, Auris Health, a subsidiary of Johnson & Johnson, and Intuitive Surgical, are investing and developing advanced endoscopy devices through flexible robotic endoscopy. Medicines and Healthcare products Regulatory Agency(MRHA), a regulatory body for medical devices of the UK, is a regulatory body governing drug and device alerts, drug safety updates, blood regulation and safety, marketing authorizations and licensing guidance, medical devices regulation and safety and many other activities. According safety guidelines by MRHA, the medical device manufacturing companies in the industry recall their medical devices if any problem or defect is detected. For instance, in February 2019, US Endoscopy Inc., an endoscopy device design and manufacturing company, voluntarily sent an urgent product recall notice to the end-users of Padlock Clip defect closure system in order to detect the problem with the device. This product was recalled as the company received a MRHA report indicating esophageal laceration during the patient procedure where Padlock Clip defect closure system was used. In order to reduce incidences associated with the endoscopy devices, with respect to MRHA safety concerns on medical devices, the company examined the implant and corrected it. Major players in the market are Olympus Corporation, Fujifilm, Boston Scientific Corporation, Conmed Corporation, and Stryker Corporation. The countries covered in the global endoscopy devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global endoscopy devices and equipment market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global endoscopy devices and equipment market is segmented - 1) By Product: Endoscope, Endoscopy Operative Devices , Endoscopy Visualization Systems 2) By Application: Bronchoscopy, Arthroscopy, Laparoscopy, Urology endoscopy, Neuroendoscopy, Gastrointestinal endoscopy, Obstetrics/gynecology endoscopy, ENT endoscopy, Others 3) By End-User: Hospitals, Clinics, Others

The antiemetics and antinauseants market consists of sale of antiemetic and antinauseant drugs and related services. Antiemetic and antinauseant drugs prevent, control or treat, nausea and vomiting caused in general or by other medications, frequent motion sickness, infections, stomach flu or chemotherapy. These drugs block signal messages to the part of the brain that controls nausea and vomiting thus reducing the symptoms of nausea or vomiting. The global antiemetics and antinauseants market is expected to grow from $2.29 billion in 2020 to $2.99 billion in 2021 at a compound annual growth rate (CAGR) of 30.6%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $3.98 billion in 2025 at a CAGR of 7.4%. The antiemetics and antinauseants market is driven by the increase in the prevalence rate of cancer. Chemotherapy is one of the most recommended treatment to cure cancer, and chemotherapy-induced nausea and vomiting (CINV) are some of the side effects of the treatment. Antiemetics can help prevent CINV in about 60%-70% of patients. According to the WHO reports, the incidence of cancer globally has risen to 18.1 million new cases and 9.6 million deaths. According to another report by Centers for Disease Control and Prevention, about 650,000 cancer patients in the USA receive chemotherapy in an outpatient oncology clinic each year. The CINV caused by chemotherapy treatments is cured by using antiemetic and antinauseant drugs like Dolasetron (Anzemet®), Ranitidine (Zantac®) and other serotonin 5-HT3 receptor types of antagonists. Increase in the incidence of cancer will increase demand for antiemetics and antinauseants, thereby driving revenue for market. Lack of awareness about the variety of antiemetic and antinauseant drugs that are available in the market among the practitioners restrains the market. Despite the presence of a range of drugs, the practitioners prescribe the similar drugs to treat patients with different conditions of nausea. Popularity of only a few drugs leads to lower the demand of other drugs and thus restricts the overall growth of this market. For example, the American Society of Clinical Oncology released its first guideline in the ‘Choosing Wisely’ (CW) campaign to prevent and discourage the overuse of expensive and similar kind of antiemetic drugs for all ailments. Manufacturers are exploiting nanotechnology in the antiemetics and antinauseants market to deliver therapeutic agents to specific targeted sites in a controlled manner through Nano medicine and Nano delivery systems. Nano medicine is the medical application of nanotechnology which uses nanoparticles to enhance the action of the drug in treatment and nanotechnology is the design, characterization, production, and application of devices, structures and systems by controlled manipulation of size and shape at the nanometer scale. The antiemetic and antinauseant drugs manufacturers are inclining more towards the use of Nano medicine or Nano drug to make the drug effective and increase their revenues. For instance, Merck & Co., an American multinational pharmaceutical company manufactured Aprepitant under the brand name Emend. It is first FDA-approved drug for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) that uses nanotechnology to increase the absorption of the drug more easily and efficiently. The antiemetics and antinauseants market is regulated by government agencies such as US Food and Drug Administration. In the USA, title 21 of Food and Drug Administration department of health and human services, U.S., part 336, contains conditions that all the Antiemetic and Antinauseant drugs are required to fulfill in order to remain in the market such as definition, regulations, and regulations related to labeling of the antiemetic drug products. In 2018, LGM Pharma, an API (active pharmaceutical ingredients) and procurement specialist acquired Zeta for an amount undisclosed. This acquisition will help LGM Pharma to broaden its portfolio of products offering to better serve the pharmaceutical industry with a broad range of drugs and complementary services. ZETA PHARMA® is an Egypt based company was established in 2010 and Zetadidox is one of the antiemetic drugs offered under Zeta's portfolio. Major players in the market are Johnson & Johnson, Sanofi-Aventis, Pfizer, GlaxoSmithKline and Abbott Laboratories. The countries covered in the global antiemetics and antinauseants market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global antiemetics and antinauseants market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global antiemetics and antinauseants market is segmented - 1) By Drug: Dopamine antagonists, NK1 receptor antagonist, Antihistamines (H1 histamine receptor antagonists), Cannabinoids, Benzodiazepines, Anticholinergics, Steroids, 5-HT3 receptor antagonists, Others 2) By Application: Chemotherapy, Motion Sickness, Gastroenteritis, General Anaesthetics, Opioid Analgesics, Dizziness, Pregnancy, Food Poisoning, Emotional Stress, Others 3) By End Users: Hospital, Medical Center, Clinic, Research Institutes

The gastrointestinal devices market consists of sales of gastrointestinal devices and related services by entities (organizations, sole traders and partnerships) that manufacture gastrointestinal devices. These devices are used for the diagnosis and treatment of medical conditions related to the digestive system or the gastrointestinal tract. Some of these products include gastroscope, enteroscope, and ultrasound endoscope. Only goods and services traded between entities or sold to end consumers are included. The global gastrointestinal devices market is expected to grow from $7.438 billion in 2020 to $7.902 billion in 2021 at a compound annual growth rate (CAGR) of 6.2%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $11.594 billion in 2025 at a CAGR of 10%. The increasing prevalence of gastrointestinal diseases contributed to the growth of the gastrointestinal devices market. Gastrointestinal diseases include irritable bowel syndrome, hemorrhoids, perianal abscesses, colon polyps, and cancer among others. According to the Endoscopy Centre, every year 62 million Americans are diagnosed with any of the digestive diseases, and 2% to 6% or an estimated 3 lakhs to 5 lakhs Americans suffer from inflammatory bowel disease (IBD). According to the American College of Gastroenterology estimates, 10-15% of the adult population in the USA suffer from irritable bowel syndrome (IBS) symptoms. The increased prevalence of gastrointestinal diseases increased the demand for gastrointestinal devices to treat patients, thereby driving the market growth. High healthcare costs for treating gastrointestinal disease restrains the gastrointestinal devices market. According to the NEJM Journal Watch, a sister publication of New England Journal of Medicine, the overall healthcare expenditure for the gastrointestinal disease is around $136 billion annually which is more than heart disease healthcare expenditure ($113 billion), trauma expenditure ($103 billion), mental health expenditure ($99 billion), indicating the high expenses involved in treating gastrointestinal disease. Moreover, a database analysis by American Gastroenterological Association states that patients with inflammatory bowel diseases (IBDs), chronic liver diseases (CLDs), functional gastrointestinal disorders (FGIDs), gastrointestinal hemorrhage are hospitalized at least once and are high-need and high-cost patients contributing disproportionately to hospitalization costs. In this context, they are the ones who are accessing inpatient services and need immense care due to functional limitation increasing the expenditure. The high healthcare expenditure for gastrointestinal disease forces the majority population to refrain from receiving treatment in non-emergency cases, which negatively impacts the growth of the gastrointestinal devices market. Single-use disposable endcap of duodenoscope is increasingly being used to prevent contamination during endoscopic retrograde cholangiopancreatography (ERCP) procedures. Single-use disposable cap controls the infection and preserves the duodenoscope optics. The USFDA recommended the hospitals and clinics to shift from reusable duodenoscopes to disposable parts duodenoscopes. The USFDA also approved the duodenoscope model featuring the disposable parts such as the PENTAX Medical ED34-i10T duodenoscope in November 2019, FUJIFILM Corporation duodenoscope model ED-580XT in March 2019, Olympus TJF-Q190V Duodenoscope in January 2020. Olympus TJF-Q190V duodenoscope is used to perform the ERCP procedure with less risk of contamination due to the disposable distal endcap. In March 2018, Boston Scientific had acquired EMcision for an undisclosed amount. The acquisition expected to expand and strengthen Boston scientific endoscopy portfolio that includes the Habib EndoHPB probe. The Habib EndoHPB probe is a new endoscopic bipolar radiofrequency device that coagulates tissue in the gastrointestinal (GI) tract. EMcision is a medical device company located in the United Kingdom and Canada. EMcision product portfolio includes Habib EndoHPB, Habib Endolate, Habib VesCoag. The major players covered in the global gastrointestinal devices market are Boston Scientific, Medtronic, Fujifilm Holdings Corporation, CONMED Corporation, Stryker Corporation, Johnson and Johnson, Olympus, Cook Group, Becton, Dickinson and Company, B. Braun Melsungen, ETHICON, Karl Storz, Congentix Medical, US Endoscopy, PENTAX Medical. The countries covered in the global gastrointestinal devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The regions covered in the global gastrointestinal devices market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global gastrointestinal devices market is segmented - 1) By Product Type: GI Videoscopes, Biopsy Devices, Endoscopic Retrograde Cholangiopancreatography Devices (ERCP), Capsule Endoscopy, Endoscopic Ultrasound, Endoscopic Mucosal Resection (EMR), Hemostasis Devices, Others 2) By End Users: Hospitals, Clinics & Dialysis Centers, Ambulatory Surgical Centers 3) By Sales Channel: Online Retailing, Medical Stores & Brand Outlets

The enzymes market consists of sales of enzymes to treat diseases. An enzyme is a protein or RNA formed by living cells that are extremely specific to its substrates and highly catalytic. Enzymes constitute a very significant class of biological macromolecular catalysts. Enzymes that are used in medical applications in their isolated or conjugated form with other drugs or therapies are known as therapeutic enzymes. Therapeutic enzymes are used in the treatment of various diseases including cancer, inflammatory disorders, cardiovascular diseases, and pain management. The global enzymes market is expected to grow from $7.81 billion in 2020 to $8.9 billion in 2021 at a compound annual growth rate (CAGR) of 14%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $15.25 billion in 2025 at a CAGR of 14%. The growing prevalence of cancer requiring drug-metabolising enzymes (DMEs) for chemotherapy is expected to drive the growth of the enzymes market in the coming years. The activation of enzymes in a human body help destroy the cancer cells and breaks down the tumor. The expression and function of drug-metabolizing enzymes (DMEs) in cancer patients' tumor tissues and metabolic organs is therefore essential and help patients for whom reaction anticancer drugs and response to chemotherapy is low. According to the World Health Organization (WHO), 9.6 million deaths occurred in 2018 due to cancer and about 70% of deaths from cancer occur in low- and middle-income countries. Therefore, the increasing prevalence of cancer that can be cured using therapeutic enzymes is predicted to drive the growth of the enzymes market. The COVID-19 outbreak hindered the growth of the enzymes market. During the COVID-19 pandemic, most companies involved in the manufacture of enzymes are currently focusing on manufacturing sanitizers to counter COVID-19. This led to a significant decline in global enzyme consumption, globally. For instance, in April 2020, BASF, the largest manufacturer of enzymes, started manufacturing hand sanitizers in New York and New Jersey to help the battle against COVID-19. Therefore, the COVID-19 outbreak limits the growth of the enzymes market. The development of new approaches to treat cancer using enzymes is a key trend gaining popularity in the enzymes market. Major universities and companies are investing in researches focusing on evolving new solutions in enzyme therapies for cancer treatment. For example, in August 2018, Kyn Therapeutics, a US-based company that focuses on improving outcomes for cancer patients along with Cancer Prevention and Research Institute of Texas and the American Cancer Society funded the research, introducing a new approach to cancer care using enzyme therapy to boost the immune system and fight back. The enzyme, PEG-KYNase, does not destroy cancer cells specifically but rather enables the immune system itself to remove unwanted cells. PEG-KYNase is designed to degrade metabolite produced by numerous tumors known as kynurenine, which suppresses the immune system. In May 2020, AbbVie Inc., an America based biopharmaceutical company acquired Allergan plc for $63 billion. This acquisition significantly expands and diversifies AbbVie's revenue base and complements existing leadership positions in Immunology, with Humira and recently launched Skyrizi and Rinvoq, and Hematologic Oncology, with Imbruvica and Venclexta. Allergan plc, an Ireland-based pharmaceutical company engaged in the research, development, and manufacture of pharmaceutical and enzymes-based therapeutic products. The major players covered in the global enzymes market are Sanofi, AbbVie Inc., Alexion Pharmaceuticals Inc, Horizon Pharma, Allergan plc, Pfizer Inc., Vivus, Digestive Care, Leadiant Biosciences, Roche Holdings AG, Codexis Inc. The countries covered in the global enzymes market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The regions covered in the global enzymes market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global enzymes market is segmented - 1) By Product Type: Asparginase, Lipase, Protease, Nattokinase, Chitinase, Serratiopeptidase, Collagenase, Ligase, Others 2) By Application: Leukemia, Stomach Disorders, Antitumor, Skin Ulcers, Gaucher Disease, Fabry Disease, Others 3) By End User: Drug Manufacturers, Hospitals, Private Clinics, Research Laboratories

The gastrointestinal drugs market consists of sales of gastrointestinal drugs by entities (organizations, sole traders and partnerships) that produce gastrointestinal drugs to treat gastrointestinal diseases such as ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome. The key gastrointestinal diseases drug categories include Anti-peptic agents (antacids, antagonists, Proton Pump Inhibitors, Sucralfate, and Misoprostol), antiemetics, adsorbents, anticholinergics, opiates, intestinal flora modifiers, emollient/surfactants, hyperosmotic, saline, and simulant/irritant. The gastrointestinal drugs market is segmented into antacids; antiulcerants; vitamin and minerals; antiobesity; antiemetics and antinauseants; and antidiarrhoeals. The global gastrointestinal drugs market is expected to grow from $46.68 billion in 2020 to $48.74 billion in 2021 at a compound annual growth rate (CAGR) of 4.4%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to reach $62.19 billion in 2025 at a CAGR of 6%. North America was the largest region in the global gastrointestinal drugs market, accounting for 48% of the market in 2020. Asia Pacific was the second largest region, accounting for 24% of the global gastrointestinal drugs market. Africa was the smallest region in the global gastrointestinal drugs market. The aging population profile of most countries contributed to the growth of the gastrointestinal drugs market. The increase in patient pool due to rising geriatric population globally contributed significantly to the growth of the market during the historic period. According to the Population Reference Bureau, the share of population over the age of 65 in the global population increased from 8% in 2015 to 9% in 2019. The global population aged 65 years or over was 703 million in 2019. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This has led to increased demand for pharmaceuticals products, significantly impacting market growth during this period. During the historic period, the growth of the gastrointestinal drugs market was restrained by patent expiration of branded gastrointestinal drugs. In general, pharmaceutical companies invest a large sum of money in the drug development process and patents. During the patency period, the company holding the patent holds exclusivity for the manufacturing and distribution of drugs. Post expiration of patency, generic versions of the drugs are manufactured by other companies with prices much lower than the original branded drugs. Overall, this negatively impacts the growth of the market in terms of value. Major companies in the gastrointestinal drug industry are investing in making oral capsules of macromolecular drugs for gastrointestinal diseases for making the drug more effective. Macromolecular drugs, such as peptides, proteins, and antibodies, form a new class of drugs which can treat diseases of the gastrointestinal tract, such as inflammatory bowel disease. These macromolecular drugs are usually injected and only a fraction of the administered dose reaches the disease sites in the gastrointestinal tract. Thus, major companies such as Eli Lilly have been increasingly investing in making oral capsules for macromolecular drugs. In December 2017, the company invested $5 million to enter into a collaboration with Entrega to study the oral delivery of complex molecules, such as peptides to combat gastrointestinal diseases. The major players covered in the global gastrointestinal drugs market are Takeda Pharmaceticals, Allergan Plc, Novo Nordisk A/S, AstraZeneca Plc, Johnson & Johnson. The countries covered in the global gastrointestinal drugs market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, Vietnam. The regions covered in the global gastrointestinal drugs market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global gastrointestinal drugs market is segmented - 1) By Type: Antacids, Antiulcerants, Vitamin And Minerals, Antiobesity, Antiemetics And Antinauseants, Antidiarrhoeals 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route Of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

Oral Biologics & Biosimilars Market Definition

The oral biologics and biosimilars market consist of sales of oral biologics and biosimilar products and related services used to treat chronic diseases such as diabetes, arthritis, and cancer. Biologics are drugs made from living cells using highly complex technology, while biosimilars are biological products which are being produced to be identical to a biologic already approved, known as reference drugs. Biosimilars should have similar safety and efficacy compared to the reference biologic product. The oral biologics and biosimilar market comprise of biologics and biosimilar drugs through oral delivery route, for the treatment of chronic diseases.